Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoimmunotherapy with blood–brain barrier opening in primary CNS lymphoma
2024-519046-79-00Phase 2Authorised
- Sponsor
- Oulu University Hospital
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab, methotrexate, etoposide phosphate, carboplatin and cyclophosphamide in primary central nervous system lymphoma (PCNSL) (3 arms), sponsored by Oulu University Hospital. Primary endpoint: Overall survival at 2, 5, and 10 years. Planned start Dec 2024; status: authorised.
02
Drugs
rituximabmethotrexateetoposide phosphatecarboplatincyclophosphamide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2024-519046-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519046-79-00.